Nine-valent human papillomavirus vaccine: implications for cervical elimination
Mené en Chine sur 9 327 femmes n'ayant jamais été vaccinées contre le papillomavirus humain, cet essai randomisé multicentrique de phase II évalue l'efficacité, la sécurité et l'immunogénicité du vaccin nonavalent produit à partir d'Escherichia coli (Cecolin 9)
In 2022, approximately 660 000 new cases of cervical cancer and 350 000 related deaths were reported, most of which occurred in low-income and middle-income countries (LMICs).1 The impact of cervical cancer in LMICs underscores the inequities driven by scarce access to national human papillomavirus (HPV) vaccination, cervical screening, and treatment services in these settings. HPV types 16 and 18 cause approximately 70–72% of cervical cancer cases globally. HPV types 31, 33, 45, 52, and 58 account for an extra 15–20% of cases, although their distribution varies by region.1 East and southeast Asia have a relatively high prevalence of HPV 52 and 58, whereas HPV 35 is more common in Africa,1,2 underscoring the benefits of multivalent HPV vaccines.
The Lancet Infectious Diseases , commentaire en libre accès, 2026